Mirati

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

Retrieved on: 
Monday, November 6, 2023
Bristol Myers Squibb, Research, National Comprehensive Cancer Network, PD-L1, Colorectal cancer, Trial of the century, NSCLC, ESMO, MAA, CHMP, Therapy, Life, Committee, Pembrolizumab, European Directive on Traditional Herbal Medicinal Products, Docetaxel, Contingent value rights, Acquisition, Committee for Medicinal Products for Human Use, Conditional, Journal of the National Comprehensive Cancer Network, Cetuximab, MHRA, Marketing, EMA, NCCN, European Medicines Agency, Immunotherapy, Colon, Lung cancer, Medicines and Healthcare products Regulatory Agency, European Society for Medical Oncology, Cancer, Investment, CVR, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry, Nursing, Mirati

SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.

Key Points: 
  • SAN DIEGO, Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the third quarter 2023 along with recent pipeline and corporate updates.
  • We look forward to continuing our work to improve the lives of people with cancer through Mirati discovered and developed therapeutics."
  • Excluding the August 2023 financing, net decrease in cash, cash equivalents and short-term investments for the third quarter of 2023 was $135.5 million.
  • Net KRAZATI product revenue for the three and nine months ended September 30, 2023 was $16.4 million and $36.1 million, respectively.

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Retrieved on: 
Friday, November 3, 2023
PD-L1, United Kingdom, NSCLC, Medication, Mirati, Lung cancer, University Hospital (Newark, New Jersey), University Hospitals Birmingham NHS Foundation Trust, MHRA, Immunotherapy, Medicines and Healthcare products Regulatory Agency, Therapy, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry

"KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.

Key Points: 
  • "KRAZATI offers a compelling therapeutic option for patients with previously treated locally advanced NSCLC with a KRASG12C mutation.
  • "Fourteen percent of people living with NSCLC harbour the KRASG12C mutation yet there are limited targeted treatment options for patients with this devastating disease1,2," said Dr Shobhit Baijal (Consultant Medical Oncologist of The University Hospital Birmingham).
  • "The expansion of treatment options for NSCLC benefits patients and clinicians alike.
  • As someone intensively involved in the management of lung cancer patients, I look forward to KRAZATI being available for use in clinical practice."

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PNT, MRTX, ORTX

Retrieved on: 
Thursday, October 26, 2023
Bristol Myers Squibb, Sale, NSCLC, MLD, Orchard, Eli Lilly, Fraud, Contingent value rights, Advertising, ADS, U.S. FDA, Patient, Mirati Therapeutics, Kyowa Kirin, Security (finance), Mirati

If you are a POINT Biopharma shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a POINT Biopharma shareholder, click here to learn more about your rights and options .
  • If you are a Mirati shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, MRTX, ICPT

Retrieved on: 
Sunday, October 22, 2023
Bristol Myers Squibb, Sale, NSCLC, Intercept Pharmaceuticals, Intercept, Fraud, Contingent value rights, Advertising, SP Plus Corporation, U.S. FDA, Patient, Mirati Therapeutics, Security (finance), Mirati

If you are a SP® Plus shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a SP® Plus shareholder, click here to learn more about your rights and options .
  • If you are a Mirati shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

MRTX Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Mirati Therapeutics, Inc. to Bristol Myers Squibb

Retrieved on: 
Friday, October 20, 2023
Bristol Myers Squibb, Wohl, Sale, CVR, Wall Street, Audit, Retail, Mirati

MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (Nasdaq: MRTX) (“Mirati”) to Bristol Myers Squibb (“Bristol Myers”) for $58.00 per share in cash, plus a contingent value right (CVR) potentially worth an additional $12.00 per share in cash.

Key Points: 
  • MONSEY, N.Y., Oct. 20, 2023 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Mirati Therapeutics, Inc. (Nasdaq: MRTX) (“Mirati”) to Bristol Myers Squibb (“Bristol Myers”) for $58.00 per share in cash, plus a contingent value right (CVR) potentially worth an additional $12.00 per share in cash.
  • If you remain a Mirati shareholder and have concerns about the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge:
    Alternatively, you may contact us by phone at 866-833-6245, or via email at [email protected] .
  • On October 8, 2023, Mirati announced that it had agreed to be sold to Bristol Myers for $58.00 per share in cash, plus a CVR potentially worth an additional $12.00 per share in cash.
  • “We are investigating whether the Mirati Board of Directors acted in the best interests of Mirati shareholders in approving the sale,” explained Joshua Fruchter, a founding partner of Wohl & Fruchter.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, OLK, ORTX, MRTX

Retrieved on: 
Wednesday, October 18, 2023
Bristol Myers Squibb, Sale, NSCLC, MLD, Orchard, Fraud, Contingent value rights, Advertising, Mindful Scientific Inc., SP Plus Corporation, Thermo Fisher Scientific, ADS, U.S. FDA, Patient, Mirati Therapeutics, Kyowa Kirin, Security (finance), Mirati

If you are a SP® Plus shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a SP® Plus shareholder, click here to learn more about your rights and options .
  • Olink Holding AB (publ) (NASDAQ: OLK)’s sale to Thermo Fisher Scientific Inc. for $26.00 per common share in cash.
  • If you are an Olink shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Tuesday, October 17, 2023
NSCLC, ESMO, Trae Waynes, DCR, Pembrolizumab, Mirati, ORR, Safety, European Society for Medical Oncology, Therapy, Patient, Mirati Therapeutics, SAN, Pharmaceutical industry

These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.

Key Points: 
  • These data demonstrate a manageable safety profile and early signs of durability of adagrasib in combination with a checkpoint inhibitor in the first-line NSCLC setting.
  • In patients with PD-L1 TPS ≥50%, adagrasib and pembrolizumab demonstrated an overall response rate (ORR) of 63% and disease control rate (DCR) of 84% and promising early signs of durability.
  • No patients discontinued both adagrasib and pembrolizumab due to ALT/AST increase or hepatic-related TRAEs.
  • Mirati plans to initiate a Phase 3 clinical study to evaluate adagrasib in combination with pembrolizumab in the first line setting for KRASG12C-mutated NSCLC with PD-L1 TPS ≥50%.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE

Retrieved on: 
Monday, October 16, 2023
NYSE, Consolidated Communications, Bristol Myers Squibb, XOM, Argos, Consolidated, Tripura Merger Agreement, Crown corporations of Canada, ExxonMobil, Brodsky, CVR, Pioneer, Searchlight Capital, BMY, Security (finance), Mirati

If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.

Key Points: 
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • The deal has a total equity value of $4.8 billion corresponding to an enterprise value of approximately $3.7 billion, which accounts for approximately $1.1 billion of Mirati cash.
  • Buyers will acquire all of the Consolidated common stock not already owned by Searchlight for $4.70 per share in cash.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, NWLI, PWFL

Retrieved on: 
Wednesday, October 11, 2023
Fraud, PowerFleet, NSCLC, Bristol Myers Squibb, U.S. FDA, National Western Life, Advertising, Patient, Therapy, Mirati Therapeutics, Contingent value rights, Sale, Security (finance), Mirati

If you are a Mirati shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Mirati shareholder, click here to learn more about your rights and options .
  • If you are a National Western shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)

Retrieved on: 
Monday, October 9, 2023
Nice, NYSE, Bristol Myers Squibb, Metropolis, NICE Ltd., Argos, Tripura Merger Agreement, Brodsky, CVR, BMY, Security (finance), Mirati

BALA CYNWYD, Pa., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • The deal has a total equity value of $4.8 billion corresponding to an enterprise value of approximately $3.7 billion, which accounts for approximately $1.1 billion of Mirati cash.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.